Clin Cancer Res:胆管癌的新预后标志物和治疗靶点——IL6和IL6R!

2020-09-19 QQY MedSci原创

血清IL6和YKL-40是胆管癌的潜在新型预后生物标志物。IL6可提供独立的预后信息,可能优于CA199。此外,应考虑将抗IL6R作为一种新的治疗选择,以维持BTC患者对吉西他滨治疗的敏感性。

胆管癌(BTC)是一种少见的胃肠道恶性肿瘤,预后不佳,常伴有炎症。Andersen等人评估了IL6和YKL-40与CA19-9在姑息性化疗前后的预后价值,并在小鼠中研究了IL6R抑制联合吉西他滨是否可延长化疗敏感期。

该研究纳入了6个临床试验(2004年-2017年)的452位晚期(局部晚期或转移性)BTC丹麦患者。姑息性化疗前后检测了血清CA199、IL6和YKL-40的水平。采用单变量和多变量Cox模型分析了候选生物标志物与无进展存活期(PFS)和总体存活期(OS)的相关性。

在晚期BTC患者中,CA199、IL6和YKL-40治疗前高水平和治疗过程中水平升高都与较短的PFS和OS相关。IL6可提供独立的预后信息,与肿瘤位置和血清CA199水平无关。ROC分析显示,IL6和YKL-40可预测非常短的OS(<6个月),而CA199最适合预测OS超过1.5年的患者的OS。在BTC的移植瘤小鼠模型中,与吉西他滨单药治疗相比,采用抗IL6R联合吉西他滨治疗可显著延缓肿瘤的生长。

综上所述,血清IL6和YKL-40是胆管癌的潜在新型预后生物标志物。IL6可提供独立的预后信息,可能优于CA199。此外,应考虑将抗IL6R作为一种新的治疗选择,以维持BTC患者对吉西他滨治疗的敏感性。

原始出处:

Jesper B. Andersen, et al. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.
Clin Cancer Res September 18 2020 DOI:10.1158/1078-0432.CCR-19-2700

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]
    2021-03-01 148bf9cam55暂无昵称

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]
    2021-03-24 echonoir
  5. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]
    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1895411, encodeId=df44189541124, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Aug 24 21:41:48 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820014, encodeId=374b182001430, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Jun 21 08:41:48 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944429, encodeId=ea379444296e, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6495327174, createdName=148bf9cam55暂无昵称, createdTime=Mon Mar 01 13:37:39 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987762, encodeId=98cc198e7627f, content=<a href='/topic/show?id=cb759e133c' target=_blank style='color:#2F92EE;'>#IL6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9713, encryptionId=cb759e133c, topicName=IL6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Wed Mar 24 04:41:48 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841576, encodeId=df7118415e673, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Apr 13 15:41:48 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886760, encodeId=298e886e606e, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=83513, encryptionId=e37c83513be, topicName=胆管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sun Sep 20 00:18:05 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542692, encodeId=a259154269286, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628457, encodeId=a562162845e44, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Mon Sep 21 14:41:48 CST 2020, time=2020-09-21, status=1, ipAttribution=)]

相关资讯

成纤维细胞生长因子受体(FGFR)抑制剂pemigatinib治疗胆管癌获得FDA的优先审查

Incyte公司的Pemigatinib用于先前治疗过的局部晚期或转移性胆管癌,已被美国食品和药物管理局(FDA)授予优先审查。

Lancet oncol:Pemigatinib可有效治疗携带FGFR2融合或重排的胆管癌

成纤维细胞生长因子受体(FGFR) 2基因变异参与了胆管癌的发病机制。Pemigatinib是一种选择性、强效的口服FGFR1、2和3抑制剂。本研究评估了pemigatinib用于有或无FGFR2融合

**胆管癌靶向治疗药物获得美国FDA批准!

Incyte制药公司近日宣布,FDA已经批准Pemazyre(pemigatinib)用于治疗先前接受过治疗,无法切除的局部晚期或转移性胆管癌患者。

FDA批准胆管癌FGFR靶向药pemigatinib获批

2020年4月18日,FDA肿瘤卓越中心主任Richard Pazdur宣布Pemazyre(pemigatinib)获批上市,该药对携带FGFR2基因融合或其他重排类型的晚期经治胆管癌患者具有良好的

PNAS:新突破:阻断一种蛋白可抑制肝癌和胆管癌

近日,西班牙科学家们发现了一种蛋白质,能够抑制肝癌和胆管癌的发展。

Lancet oncol:达拉非尼联合曲美替尼治疗BRAF V600E突变的胆管癌

BRAF基因突变见于5%的胆道肿瘤患者。达拉非尼和曲美替尼的联合方案在几种BRAF(V600E)突变的癌症中显示出抗肿瘤活性。本研究目的是评估达该联合方案用于携带BRAF突变的胆管癌的疗效和安全性